{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:59:12Z","timestamp":1788260352896,"version":"build-2803163510"},"reference-count":207,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtauto.2024.100264","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T15:08:25Z","timestamp":1734361705000},"page":"100264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Cellular therapies in rheumatic and musculoskeletal diseases"],"prefix":"10.1016","volume":"10","author":[{"given":"Pedro","family":"Franco-Fuquen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Figueroa-Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eider F.","family":"Moreno-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan E.","family":"Garcia-Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vargas-Cely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela A.","family":"Castro-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Almaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Januario E.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jtauto.2024.100264_bib1","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/art.41812","article-title":"Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases?","volume":"73","author":"Orvain","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.40448","volume":"70","author":"van der Heijde","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10067-014-2841-6","article-title":"The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases","volume":"34","author":"Al Maini","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.semarthrit.2008.01.004","article-title":"Multimorbidity: prevalence, effect on quality of life and daily functioning, and variation of this effect when one condition is a rheumatic disease","volume":"38","author":"Loza","year":"2009","journal-title":"Semin. Arthritis Rheum."},{"issue":"9859","key":"10.1016\/j.jtauto.2024.100264_bib5","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"issue":"9194","key":"10.1016\/j.jtauto.2024.100264_bib7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jtauto.2024.100264_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1089\/hum.2014.2532","article-title":"From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies\/chimeric antigen receptor T cells","volume":"25","author":"Eshhar","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"9","key":"10.1016\/j.jtauto.2024.100264_bib9","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/eji.202049064","article-title":"CAR T cells: building on the CD19 paradigm","volume":"51","author":"Globerson Levin","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib10","first-page":"467","article-title":"Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtauto.2024.100264_bib11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10254","key":"10.1016\/j.jtauto.2024.100264_bib15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.jtauto.2024.100264_bib18","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"16","key":"10.1016\/j.jtauto.2024.100264_bib19","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"303","key":"10.1016\/j.jtauto.2024.100264_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2017.03.002","article-title":"CARs: synthetic immunoreceptors for cancer therapy and beyond","volume":"23","author":"Chang","year":"2017","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"24","key":"10.1016\/j.jtauto.2024.100264_bib23","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1016\/j.cell.2022.10.026","article-title":"CAR T therapy extends its reach to autoimmune diseases","volume":"185","author":"Baker","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12810","article-title":"BAFF inhibition in SLE-Is tolerance restored?","volume":"292","author":"Jackson","year":"2019","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2024.100264_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J. Autoimmun."},{"issue":"482","key":"10.1016\/j.jtauto.2024.100264_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jtauto.2024.100264_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"10","key":"10.1016\/j.jtauto.2024.100264_bib31","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib32","article-title":"Defining response characteristics","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/1744666X.2019.1573672","article-title":"B-cell depleting immunotherapies: therapeutic opportunities and toxicities","volume":"15","author":"Del Bufalo","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"issue":"Supplement 1","key":"10.1016\/j.jtauto.2024.100264_bib34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtauto.2024.100264_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib36","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0092-8674(91)90327-U","article-title":"Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides","volume":"64","author":"Romeo","year":"1991","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.jtauto.2024.100264_bib37","doi-asserted-by":"crossref","first-page":"11478","DOI":"10.1073\/pnas.94.21.11478","article-title":"Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells","volume":"94","author":"Yang","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.jtauto.2024.100264_bib38","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V84.9.2878.2878","article-title":"Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors","volume":"84","author":"Roberts","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.gt.3302413","article-title":"T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120","volume":"12","author":"Masiero","year":"2005","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib40","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.4049\/jimmunol.155.2.1000","article-title":"Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes","volume":"155","author":"Tran","year":"1995","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib41","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/mt.2015.102","article-title":"HIV-Specific immunity derived from chimeric antigen receptor-engineered stem cells","volume":"23","author":"Zhen","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jtauto.2024.100264_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-immunol-032713-120136","article-title":"Adoptive immunotherapy for cancer or viruses","volume":"32","author":"Maus","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib43","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"issue":"132","key":"10.1016\/j.jtauto.2024.100264_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.jtauto.2024.100264_bib45","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.2174\/1871520620666200317105207","article-title":"Copanlisib: novel PI3K inhibitor for the treatment of lymphoma","volume":"20","author":"Kumar","year":"2020","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"95","key":"10.1016\/j.jtauto.2024.100264_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"26","key":"10.1016\/j.jtauto.2024.100264_bib47","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"12","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.jtauto.2024.100264_bib48","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10299","key":"10.1016\/j.jtauto.2024.100264_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"10297","key":"10.1016\/j.jtauto.2024.100264_bib50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"10402","key":"10.1016\/j.jtauto.2024.100264_bib51","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib52","first-page":"316","article-title":"[Next generation engineered T cells for cell therapy: from lymphoma to solid tumors]","volume":"35","author":"Catros","year":"2019","journal-title":"Med. Sci."},{"key":"10.1016\/j.jtauto.2024.100264_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.639818","article-title":"The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol. Rev."},{"issue":"24","key":"10.1016\/j.jtauto.2024.100264_bib55","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2024.100264_bib57","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtauto.2024.100264_bib58","doi-asserted-by":"crossref","first-page":"vi326","DOI":"10.1093\/annonc\/mdw375.40","article-title":"ZUMA-2: a phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed\/refractory Mantle cell lymphoma (R\/R MCL)","volume":"27","author":"Wang","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jtauto.2024.100264_bib59","article-title":"Chimeric antigen receptor T cell therapy in oncology - pipeline at a glance: analysis of the ClinicalTrials.gov database","author":"Moreno","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jtauto.2024.100264_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200914","article-title":"ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype","volume":"13","author":"Moreno-Cortes","year":"2023","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034629","article-title":"Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)","volume":"10","author":"George","year":"2020","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026644","article-title":"Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I\/II clinical trial protocol","volume":"9","author":"Schubert","year":"2019","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib63","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","article-title":"In vivo expansion and antitumor activity of coinfused CD28- and 4-1BB-engineered CAR-T cells in patients with B cell leukemia","volume":"26","author":"Cheng","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jtauto.2024.100264_bib64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jtauto.2024.100264_bib65","first-page":"384","article-title":"A next-generation chimeric antigen receptor induces JAK-STAT signaling. Cancer discov.(c)","volume":"4","year":"2018","journal-title":"American Association for Cancer Research"},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib66","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib67","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032413","article-title":"Cell immunotherapy against melanoma: clinical trials review","volume":"24","author":"Filin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib69","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12967-022-03437-0","article-title":"Natural killer cells: a promising immunotherapy for cancer","volume":"20","author":"Chu","year":"2022","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib70","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.trecan.2021.10.007","article-title":"Exploiting T cell signaling to optimize engineered T cell therapies","volume":"8","author":"Wang","year":"2022","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib72","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2326-6066.CIR-21-0307","article-title":"A costimulatory CAR improves TCR-based cancer immunotherapy","volume":"10","author":"Omer","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"14","key":"10.1016\/j.jtauto.2024.100264_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20143500","article-title":"Beyond TCR signaling: emerging functions of lck in cancer and immunotherapy","volume":"20","author":"Bommhardt","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib74","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4161\/hv.7.5.14652","article-title":"Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers","volume":"7","author":"Anguille","year":"2011","journal-title":"Hum Vaccin"},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib75","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/21645515.2015.1009814","article-title":"Clinically feasible approaches to potentiating cancer cell-based immunotherapies","volume":"11","author":"Seledtsov","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib76","first-page":"228","article-title":"[Influencing factors and significance of tumor-associated macrophage polarization in tumor microenvironment]","volume":"26","author":"Ge","year":"2023","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"Suppl 5","key":"10.1016\/j.jtauto.2024.100264_bib77","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1289\/ehp.99107s5661","article-title":"Introduction to immunology and autoimmunity","volume":"107","author":"Smith","year":"1999","journal-title":"Environ. Health Perspect."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib78","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1172\/JCI78088","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jtauto.2024.100264_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102266","article-title":"The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention","volume":"80","author":"Miller","year":"2023","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib80","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1535-6108(03)00113-2","article-title":"Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction","volume":"3","author":"Ho","year":"2003","journal-title":"Cancer Cell"},{"issue":"25","key":"10.1016\/j.jtauto.2024.100264_bib81","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib83","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.jtauto.2024.100264_bib84","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib85","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/art.30152","article-title":"Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib86","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/rheumatology\/kez430","article-title":"Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy","volume":"59","author":"Combier","year":"2020","journal-title":"Rheumatology"},{"issue":"26","key":"10.1016\/j.jtauto.2024.100264_bib87","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jtauto.2024.100264_bib88","first-page":"669","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jtauto.2024.100264_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1034257","article-title":"Mechanisms of CAR T cell exhaustion and current counteraction strategies","volume":"10","author":"Zhu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib91","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.jtauto.2024.100264_bib90","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"20 Pt 1","key":"10.1016\/j.jtauto.2024.100264_bib92","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.jtauto.2024.100264_bib93","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"12","key":"10.1016\/j.jtauto.2024.100264_bib94","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1089\/hum.2005.16.1452","article-title":"Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression","volume":"16","author":"Lamers","year":"2005","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib95","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.jtauto.2024.100264_bib96","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/annrheumdis-2023-eular.3736","article-title":"OP0141 long term safety and efficacy of car-t cell treatment in refractory systemic lupus erythematosus - data from the first seven patients","volume":"82","author":"Taubmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib97","doi-asserted-by":"crossref","DOI":"10.4110\/in.2022.22.e37","article-title":"Engineering cell therapies for autoimmune diseases: from preclinical to clinical proof of concept","volume":"22","author":"Oh","year":"2022","journal-title":"Immune Netw"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib98","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"6295","key":"10.1016\/j.jtauto.2024.100264_bib99","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.jtauto.2024.100264_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100645","article-title":"Autoimmunity as a target for chimeric immune receptor therapy: a new vision to therapeutic potential","volume":"41","author":"Haddadi","year":"2020","journal-title":"Blood Rev."},{"issue":"12","key":"10.1016\/j.jtauto.2024.100264_bib101","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jtauto.2024.100264_bib102","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3389\/fimmu.2018.02359","article-title":"Chimeric antigen receptor (CAR) Treg: a promising approach to inducing immunological tolerance","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib103","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jtauto.2024.100264_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108409","article-title":"CAR Treg: a new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.jtauto.2024.100264_bib105","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib106","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jtauto.2024.100264_bib107","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.imlet.2018.10.001","article-title":"Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population","volume":"204","author":"Hashemi","year":"2018","journal-title":"Immunol. Lett."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib108","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2337\/db09-0694","article-title":"Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects","volume":"59","author":"Long","year":"2010","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib109","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.autrev.2009.01.004","article-title":"Identification of regulatory T cells in systemic lupus erythematosus","volume":"8","author":"Gerli","year":"2009","journal-title":"Autoimmun. Rev."},{"issue":"9","key":"10.1016\/j.jtauto.2024.100264_bib110","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.4049\/jimmunol.177.9.5852","article-title":"Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis","volume":"177","author":"Uhlig","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2024.100264_bib111","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3389\/fimmu.2020.01608","article-title":"The future of regulatory T cell therapy: promises and challenges of implementing CAR technology","volume":"11","author":"Mohseni","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib113","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"issue":"11","key":"10.1016\/j.jtauto.2024.100264_bib114","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41587-021-01115-y","volume":"39","author":"Dolgin","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.autrev.2017.11.018","article-title":"NK cells in autoimmune diseases: linking innate and adaptive immune responses","volume":"17","author":"Gianchecchi","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2024.100264_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.616853","article-title":"Natural killer cells: potential biomarkers and therapeutic target in autoimmune diseases?","volume":"12","author":"Gianchecchi","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib117","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10875-011-9542-6","article-title":"Combined treatment of etanercept and MTX reverses Th1\/Th2, Th17\/Treg imbalance in patients with rheumatoid arthritis","volume":"31","author":"Lina","year":"2011","journal-title":"J. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib118","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0952-7915(02)00408-9","article-title":"CD4(+) regulatory T cells in autoimmunity and allergy","volume":"14","author":"Curotto de Lafaille","year":"2002","journal-title":"Curr. Opin. Immunol."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib119","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.coi.2005.09.002","article-title":"How do CD4+CD25+ regulatory T cells control autoimmunity?","volume":"17","author":"Bluestone","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jtauto.2024.100264_bib120","article-title":"NK cells in autoimmune diseases: protective or pathogenic?","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2024.100264_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.622306","article-title":"The role of natural killer cells in autoimmune diseases","volume":"12","author":"Kucuksezer","year":"2021","journal-title":"Front. Immunol."},{"issue":"7293","key":"10.1016\/j.jtauto.2024.100264_bib122","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/nature08933","article-title":"Genetics, pathogenesis and clinical interventions in type 1 diabetes","volume":"464","author":"Bluestone","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib123","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni771","article-title":"Target cell defense prevents the development of diabetes after viral infection","volume":"3","author":"Flodstr\u00f6m","year":"2002","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib124","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.4049\/jimmunol.0804358","article-title":"Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice","volume":"184","author":"Brauner","year":"2010","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/rheumatology\/keu363","article-title":"High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis","volume":"54","author":"Da\u00efen","year":"2015","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.jtauto.2024.100264_bib126","first-page":"2484","article-title":"FcgammaRIII engagement provides activating signals to NKT cells in antibody-induced joint inflammation","volume":"116","author":"Kim","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib127","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bbrc.2009.09.008","article-title":"Natural killer T cells promote collagen-induced arthritis in DBA\/1 mice","volume":"390","author":"Jung","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib128","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2567.2009.03235.x","article-title":"Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment","volume":"130","author":"Miellot-Gafsou","year":"2010","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib129","first-page":"1223","article-title":"Natural killer cell activity in the systemic connective tissue diseases","volume":"15","author":"Gonzalez-Amaro","year":"1988","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12016-015-8505-8","article-title":"T and NK cell phenotypic abnormalities in systemic sclerosis: a cohort study and a comprehensive literature review","volume":"49","author":"Almeida","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib131","article-title":"Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep Med"},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib132","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nri3447","article-title":"The good, the bad and the ugly - TFH cells in human health and disease","volume":"13","author":"Tangye","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib133","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrrheum.2012.58","article-title":"Follicular helper T cells in immunity and systemic autoimmunity","volume":"8","author":"Craft","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.jtauto.2024.100264_bib134","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri2637","article-title":"Dysregulation of germinal centres in autoimmune disease","volume":"9","author":"Vinuesa","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/eji.201545760","article-title":"T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis","volume":"46","author":"Blanco","year":"2016","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib136","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/art.39020","article-title":"Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity","volume":"67","author":"Choi","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib137","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.20081886","article-title":"Follicular helper T cells are required for systemic autoimmunity","volume":"206","author":"Linterman","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2024.100264_bib138","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","article-title":"Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering","volume":"51","author":"Daher","year":"2018","journal-title":"Curr. Opin. Immunol."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib139","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib140","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.joms.2007.04.008","article-title":"Adult mesenchymal stem cells: biological properties, characteristics, and applications in maxillofacial surgery","volume":"65","author":"Shanti","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib141","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib142","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jcyt.2021.10.003","article-title":"Rheumatoid arthritis: from synovium biology to cell-based therapy","volume":"24","author":"Debreova","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtauto.2024.100264_bib143","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/nyas.12815","article-title":"The immunomodulatory function of mesenchymal stem cells: mode of action and pathways","volume":"1351","author":"Uccelli","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib144","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/art.24405","article-title":"Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells","volume":"60","author":"Gonz\u00e1lez","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/ard.2008.101881","article-title":"Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis","volume":"69","author":"Gonzalez-Rey","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib146","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00296-019-04296-7","article-title":"Secretory factors produced by adipose mesenchymal stem cells downregulate Th17 and increase Treg cells in peripheral blood mononuclear cells from rheumatoid arthritis patients","volume":"39","author":"Vasilev","year":"2019","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib147","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4049\/jimmunol.0902007","article-title":"Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype","volume":"185","author":"Ghannam","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib148","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/icb.2013.55","article-title":"Human T follicular helper (Tfh) cells and disease","volume":"92","author":"Ma","year":"2014","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib149","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10067-011-1816-0","article-title":"Allogeneic mesenchymal stem cells transplantation in patients with refractory RA","volume":"31","author":"Liang","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jtauto.2024.100264_bib150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1479-5876-9-181","article-title":"Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells","volume":"9","author":"Ra","year":"2011","journal-title":"J. Transl. Med."},{"issue":"24","key":"10.1016\/j.jtauto.2024.100264_bib151","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1089\/scd.2013.0023","article-title":"Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy","volume":"22","author":"Wang","year":"2013","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.jtauto.2024.100264_bib152","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.2147\/DDDT.S225613","article-title":"Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I\/II study","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib153","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"\u00c1lvaro-Gracia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2024.100264_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103427","article-title":"Mesenchymal stem\/stromal cell-based therapy for the treatment of rheumatoid arthritis: an update on preclinical studies","volume":"69","author":"Lopez-Santalla","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jtauto.2024.100264_bib155","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.12659\/MSM.911184","article-title":"Treatment of type II collagen-induced rat rheumatoid arthritis model by interleukin 10 (IL10)-Mesenchymal stem cells (BMSCs)","volume":"25","author":"Tian","year":"2019","journal-title":"Med Sci Monit"},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib156","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2249.2008.03683.x","article-title":"Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice","volume":"153","author":"Choi","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib157","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/art.30326","article-title":"Transforming growth factor \u03b2-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg\/Th17 cells and osteoclastogenesis","volume":"63","author":"Park","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2024.100264_bib158","doi-asserted-by":"crossref","DOI":"10.1038\/srep35933","article-title":"Overexpression of soluble RAGE in mesenchymal stem cells enhances their immunoregulatory potential for cellular therapy in autoimmune arthritis","volume":"6","author":"Park","year":"2016","journal-title":"Sci. Rep."},{"issue":"24","key":"10.1016\/j.jtauto.2024.100264_bib159","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1089\/scd.2013.0248","article-title":"Allogeneic murine mesenchymal stem cells: migration to inflamed joints in vivo and amelioration of collagen induced arthritis when transduced to express CTLA4Ig","volume":"22","author":"Sullivan","year":"2013","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.jtauto.2024.100264_bib160","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2024.100264_bib161","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221100294","article-title":"Cell-based therapies for rheumatoid arthritis: opportunities and challenges","volume":"14","author":"Li","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jtauto.2024.100264_bib162","article-title":"B cells in rheumatoid arthritis:pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib163","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of systemic lupus erythematosus","volume":"16","author":"Pan","year":"2020","journal-title":"World J Pediatr"},{"key":"10.1016\/j.jtauto.2024.100264_bib164","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fimmu.2014.00164","article-title":"Breaking immunological tolerance in systemic lupus erythematosus","volume":"5","author":"Pieterse","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2024.100264_bib165","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3389\/fimmu.2020.01353","article-title":"Current insights in cutaneous lupus erythematosus immunopathogenesis","volume":"11","author":"Garelli","year":"2020","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.jtauto.2024.100264_bib166","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246231","article-title":"B cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments","volume":"20","author":"Yap","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5387\/fms.2020-02","article-title":"Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers","volume":"66","author":"Sato","year":"2020","journal-title":"Fukushima J. Med. Sci."},{"issue":"10","key":"10.1016\/j.jtauto.2024.100264_bib168","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1191\/0961203305lu2187oa","article-title":"Serositis related to systemic lupus erythematosus: prevalence and outcome","volume":"14","author":"Man","year":"2005","journal-title":"Lupus"},{"issue":"13","key":"10.1016\/j.jtauto.2024.100264_bib169","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1177\/0961203319883680","article-title":"Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a single-center experience with 63 patients","volume":"28","author":"Nieto-Aristiz\u00e1bal","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.jtauto.2024.100264_bib170","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fmed.2020.00316","article-title":"B cell therapy in systemic lupus erythematosus: from rationale to clinical practice","volume":"7","author":"Parodis","year":"2020","journal-title":"Front. Med."},{"issue":"7949","key":"10.1016\/j.jtauto.2024.100264_bib171","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.jtauto.2024.100264_bib172","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib173","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib174","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib175","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib176","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"Pope","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100264_bib177","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41584-022-00765-9","article-title":"Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need","volume":"18","author":"Herrick","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jtauto.2024.100264_bib178","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","author":"Bergmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"5638","key":"10.1016\/j.jtauto.2024.100264_bib179","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.jtauto.2024.100264_bib180","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jtauto.2024.100264_bib181","article-title":"An updated review of pemphigus diseases","volume":"57","author":"Malik","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib182","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1590\/abd1806-4841.20199011","article-title":"Pemphigus vulgaris","volume":"94","author":"Porro","year":"2019","journal-title":"An. Bras. Dermatol."},{"issue":"175","key":"10.1016\/j.jtauto.2024.100264_bib183","doi-asserted-by":"crossref","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib184","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/mt.2016.165","article-title":"Like angler fish, CAARs lure their prey","volume":"24","author":"Galy","year":"2016","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9911","key":"10.1016\/j.jtauto.2024.100264_bib186","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jtauto.2024.100264_bib187","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1323436111","article-title":"Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7039","key":"10.1016\/j.jtauto.2024.100264_bib188","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nature03523","article-title":"Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice","volume":"435","author":"Nakayama","year":"2005","journal-title":"Nature"},{"issue":"40","key":"10.1016\/j.jtauto.2024.100264_bib189","doi-asserted-by":"crossref","first-page":"16729","DOI":"10.1073\/pnas.1113954108","article-title":"Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse","volume":"108","author":"Crawford","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.jtauto.2024.100264_bib190","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1073\/pnas.1006545107","article-title":"Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register","volume":"107","author":"Stadinski","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"10.1016\/j.jtauto.2024.100264_bib191","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/dmrr.1250","article-title":"Insulin as a key autoantigen in the development of type 1 diabetes","volume":"27","author":"Nakayama","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jtauto.2024.100264_bib192","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12896-015-0125-0","article-title":"Generation and analysis of the improved human HAL9\/10 antibody phage display libraries","volume":"15","author":"K\u00fcgler","year":"2015","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.jtauto.2024.100264_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","author":"Tenspolde","year":"2019","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib194","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100264_bib195","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma - PubMed","volume":"18","author":"Ld","year":"2022","journal-title":"Future oncology (London, England)"},{"issue":"Suppl 3","key":"10.1016\/j.jtauto.2024.100264_bib196","article-title":"CAR T-cell therapy: adverse events and management - PubMed","volume":"10","author":"S","year":"2019","journal-title":"Journal of the advanced practitioner in oncology"},{"key":"10.1016\/j.jtauto.2024.100264_bib197","article-title":"Toxicity and management in CAR T-cell therapy - PubMed","author":"Cl","year":"2016","journal-title":"Molecular therapy oncolytics"},{"key":"10.1016\/j.jtauto.2024.100264_bib201","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib198","article-title":"New insights in systemic lupus erythematosus: from regulatory T cells to CAR-T-cell strategies - PubMed","volume":"150","author":"M","year":"2022","journal-title":"The Journal of allergy and clinical immunology"},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib202","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jgo.2020.08.004","article-title":"Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies","volume":"12","author":"Jaggers","year":"2021","journal-title":"J Geriatr Oncol. Mar"},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib203","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100264_bib204","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin. Mar"},{"issue":"4","key":"10.1016\/j.jtauto.2024.100264_bib205","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1502","article-title":"Chimeric antigen receptor T cells in the fast lane among autoimmune disease therapies","volume":"13","author":"Ding","year":"2024","journal-title":"Clin Transl Immunology"},{"issue":"6","key":"10.1016\/j.jtauto.2024.100264_bib206","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jaci.2022.08.003","article-title":"(EBMT) ADWPAotESfBaMT. New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies","volume":"150","author":"Doglio","year":"2022","journal-title":"J. Allergy Clin. Immunol. Dec"},{"issue":"20","key":"10.1016\/j.jtauto.2024.100264_bib207","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100264_bib208","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.jtauto.2024.100264_bib199","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10","key":"10.1016\/j.jtauto.2024.100264_bib200","doi-asserted-by":"crossref","DOI":"10.3390\/cells13100797","article-title":"Targeted therapy of multiple sclerosis: a case for antigen-specific Tregs","volume":"13","author":"Zhong","year":"2024","journal-title":"Cells"}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909024000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909024000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:16:02Z","timestamp":1762632962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909024000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":207,"alternative-id":["S2589909024000340"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2024.100264","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular therapies in rheumatic and musculoskeletal diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2024.100264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100264"}}